home / stock / glto / glto news


GLTO News and Press, Galecto Inc.

Stock Information

Company Name: Galecto Inc.
Stock Symbol: GLTO
Market: NASDAQ
Website: galecto.com

Menu

GLTO GLTO Quote GLTO Short GLTO News GLTO Articles GLTO Message Board
Get GLTO Alerts

News, Short Squeeze, Breakout and More Instantly...

GLTO - GLTO Stock Earnings: Galecto Beats EPS for Q1 2024

2024-05-03 10:54:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galecto (NASDAQ: GLTO ) just reported results for the first quarter of 2024. Galecto reported earnings per share of -20 cents. This was above the analyst estimate for EPS ...

GLTO - Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that the first patient has been enrolled in an investigator-initiated Phase 2 trial to evaluate GB1...

GLTO - Expected US Company Earnings on Friday, April 26th, 2024

Morgan Advanced Materials Plc (MCRUF) is expected to report for Q4 2023 Security Federal Corp (SFDL) is expected to report for Q1 2024 Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q1 2024 OMV AG (OMVJF) is expected to report $1.91 for Q1 2024 Pola Orbis ...

GLTO - GLTO Stock Earnings: Galecto Beats EPS for Q4 2023

2024-03-15 13:53:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galecto (NASDAQ: GLTO ) just reported results for the fourth quarter of 2023. Galecto reported earnings per share of -22 cents. This was above the analyst estimate for EPS...

GLTO - Galecto stock rallies 25% on positive data for myelofibrosis drug

2023-12-21 16:40:39 ET More on Galecto Galecto reduces workforce by 70%, explores potential strategic alternatives Seeking Alpha’s Quant Rating on Galecto Historical earnings data for Galecto Financial information for Galecto For further detail...

GLTO - Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

BOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive topline results from a Phase 2a trial of GB2064 for the treatment of myelofibrosis (the &...

GLTO - Expected earnings - Galecto Inc.

Galecto Inc. (GLTO) is expected to report $-0.47 for Q3 2023

GLTO - Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today presented a poster with new and encouraging clinical data, including two additional partial responders, from...

GLTO - 24/7 Market News Lunch Break 27 Sept 2023

2023-09-27 12:18:23 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; ShiftPixy Inc (NASDAQ: PIXY), SciSparc Ltd (NASDAQ: SPRC), Galecto Inc (NASDAQ: GLTO), American Strate...

GLTO - 24/7 Market News Snapshot 27 Sept 2023

2023-09-27 09:55:35 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; ShiftPixy Inc (NASDAQ: PIXY), Galecto Inc (NASDAQ: GLTO), Cardiff Oncology Inc (NASDAQ: CRDF), American Strat...

Next 10